In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...

Earnings per share (EPS) missed analyst estimates significantly ... compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

Shares of Teva Pharmaceutical Industries ( TEVA -2.29%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.01%) and Nasdaq ...

Teva Pharmaceutical Industries' Q4 2024 results ... A 12-month price target of $25/share, 10x FY 2025 non-GAAP EPS estimates seems achievable should Teva outperform lowered EPS and sales estimates.

Teva Pharmaceutical (NYSE ... The stock closed 1.67% lower at $17.06 on Tuesday. Despite topping Q4 EPS and revenue expectations, shares of TEVA declined 13% on January 29 as the drugmaker set ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva Pharmaceutical ...

JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA ... For all of 2024, Teva recorded diluted EPS of $2.49 ex-items - above estimates of $2.47 - compared with $2.56 in 2023.

Shares of Teva Pharmaceutical Industries (NYSE ... Its earnings per share (EPS) for Q4 was $0.71, down significantly from Q4 2023's $1.00, but slightly exceeding an expected $0.70.